Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Risk factors for Clostridioides difficile infection in hospitalized patients and associated mortality in Japan: a multi-centred prospective cohort study.

Honda H, Kato H, Olsen MA, Reske KA, Senoh M, Fukuda T, Tagashira Y, Mahe C, Dubberke ER; Clostridioides difficile infection Japan study group.

J Hosp Infect. 2019 Sep 19. pii: S0195-6701(19)30400-1. doi: 10.1016/j.jhin.2019.09.012. [Epub ahead of print]

PMID:
31542458
2.

Comparative Genomics of Antibiotic-Resistant Uropathogens Implicates Three Routes for Recurrence of Urinary Tract Infections.

Thänert R, Reske KA, Hink T, Wallace MA, Wang B, Schwartz DJ, Seiler S, Cass C, Burnham CA, Dubberke ER, Kwon JH, Dantas G.

MBio. 2019 Aug 27;10(4). pii: e01977-19. doi: 10.1128/mBio.01977-19.

3.

Metabolomic networks connect host-microbiome processes to human Clostridioides difficile infections.

Robinson JI, Weir WH, Crowley JR, Hink T, Reske KA, Kwon JH, Burnham CD, Dubberke ER, Mucha PJ, Henderson JP.

J Clin Invest. 2019 Aug 12;130:3792-3806. doi: 10.1172/JCI126905. eCollection 2019 Aug 12.

4.

Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II.

Wilcox MH, Rahav G, Dubberke ER, Gabryelski L, Davies K, Berry C, Eves K, Ellison MC, Guris D, Dorr MB.

Open Forum Infect Dis. 2019 Aug 1;6(8). pii: ofz293. doi: 10.1093/ofid/ofz293.

5.

A national survey of testing and management of asymptomatic carriage of C. difficile.

Kutty PK, Beekmann SE, Sinkowitz-Cochran RL, Dubberke ER, Kuhar DT, McDonald LC, Polgreen PM.

Infect Control Hosp Epidemiol. 2019 Jul;40(7):801-803. doi: 10.1017/ice.2019.109. Epub 2019 May 20.

PMID:
31106723
6.

Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice.

Mullane KM, Dubberke ER; AST ID Community of Practice.

Clin Transplant. 2019 Apr 19:e13564. doi: 10.1111/ctr.13564. [Epub ahead of print]

PMID:
31002420
7.

Cytomegalovirus Infections of the Stem Cell Transplant Recipient and Hematologic Malignancy Patient.

Pande A, Dubberke ER.

Infect Dis Clin North Am. 2019 Jun;33(2):485-500. doi: 10.1016/j.idc.2019.02.008. Epub 2019 Mar 30. Review.

PMID:
30940460
8.

Clostridioides (Clostridium) difficile infection burden in Japan: A multicenter prospective study.

Kato H, Senoh M, Honda H, Fukuda T, Tagashira Y, Horiuchi H, Chiba H, Suzuki D, Hosokawa N, Kitazono H, Norisue Y, Kume H, Mori N, Morikawa H, Kashiwagura S, Higuchi A, Kato H, Nakamura M, Ishiguro S, Morita S, Ishikawa H, Watanabe T, Kojima K, Yokomaku I, Bando T, Toimoto K, Moriya K, Kasahara K, Kitada S, Ogawa J, Saito H, Tominaga H, Shimizu Y, Masumoto F, Tadera K, Yoshida J, Kikuchi T, Yoshikawa I, Watanabe T, Honda M, Yokote K, Toyokawa T, Miyazato H, Nakama M, Mahe C, Reske K, Olsen MA, Dubberke ER.

Anaerobe. 2019 Mar 12. pii: S1075-9964(19)30046-0. doi: 10.1016/j.anaerobe.2019.03.007. [Epub ahead of print]

PMID:
30872073
9.

Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential.

Bulow C, Langdon A, Hink T, Wallace M, Reske KA, Patel S, Sun X, Seiler S, Jones S, Kwon JH, Burnham CA, Dantas G, Dubberke ER.

mSphere. 2018 Nov 21;3(6). pii: e00588-18. doi: 10.1128/mSphereDirect.00588-18.

10.

Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials.

Basu A, Prabhu VS, Dorr MB, Golan Y, Dubberke ER, Cornely OA, Heimann SM, Pedley A, Xu R, Hanson ME, Marcella S.

Open Forum Infect Dis. 2018 Nov 15;5(11):ofy218. doi: 10.1093/ofid/ofy218. eCollection 2018 Nov.

11.

Clostridium difficile infection increases acute and chronic morbidity and mortality.

Olsen MA, Stwalley D, Demont C, Dubberke ER.

Infect Control Hosp Epidemiol. 2019 Jan;40(1):65-71. doi: 10.1017/ice.2018.280. Epub 2018 Nov 9.

PMID:
30409240
12.

Clostridium difficile colonization among patients with clinically significant diarrhea and no identifiable cause of diarrhea.

Dubberke ER, Reske KA, Hink T, Kwon JH, Cass C, Bongu J, Burnham CD, Henderson JP.

Infect Control Hosp Epidemiol. 2018 Nov;39(11):1330-1333. doi: 10.1017/ice.2018.225. Epub 2018 Sep 18.

PMID:
30226126
13.

An Assessment of Inappropriate Antibiotic Use and Guideline Adherence for Uncomplicated Urinary Tract Infections.

Durkin MJ, Keller M, Butler AM, Kwon JH, Dubberke ER, Miller AC, Polgreen PM, Olsen MA.

Open Forum Infect Dis. 2018 Aug 10;5(9):ofy198. doi: 10.1093/ofid/ofy198. eCollection 2018 Sep.

14.

Reply to Million et al.

Dubberke ER, Blount K, Gerding DN.

Clin Infect Dis. 2018 Nov 13;67(11):1799-1800. doi: 10.1093/cid/ciy460. No abstract available.

PMID:
30084881
15.

Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.

Prabhu VS, Cornely OA, Golan Y, Dubberke ER, Heimann SM, Hanson ME, Liao J, Pedley A, Dorr MB, Marcella S.

Clin Infect Dis. 2017 Oct 1;65(7):1218-1221. doi: 10.1093/cid/cix523.

16.

Increasing Age Has Limited Impact on Risk of Clostridium difficile Infection in an Elderly Population.

Olsen MA, Stwalley D, Demont C, Dubberke ER.

Open Forum Infect Dis. 2018 Jul 19;5(7):ofy160. doi: 10.1093/ofid/ofy160. eCollection 2018 Jul.

17.

A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation.

Mullane KM, Winston DJ, Nooka A, Morris MI, Stiff P, Dugan MJ, Holland H, Gregg K, Adachi JA, Pergam SA, Alexander BD, Dubberke ER, Broyde N, Gorbach SL, Sears PS.

Clin Infect Dis. 2019 Jan 7;68(2):196-203. doi: 10.1093/cid/ciy484. Erratum in: Clin Infect Dis. 2019 Mar 19;68(7):1254.

18.

Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection.

Dubberke ER, Lee CH, Orenstein R, Khanna S, Hecht G, Gerding DN.

Clin Infect Dis. 2018 Sep 28;67(8):1198-1204. doi: 10.1093/cid/ciy259.

PMID:
29617739
19.

Frequency of Instrument, Environment, and Laboratory Technologist Contamination during Routine Diagnostic Testing of Infectious Specimens.

Yarbrough ML, Kwon JH, Wallace MA, Hink T, Shupe A, Fraser VJ, Dubberke ER, Burnham CA.

J Clin Microbiol. 2018 May 25;56(6). pii: e00225-18. doi: 10.1128/JCM.00225-18. Print 2018 Jun.

20.

Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH.

Clin Infect Dis. 2018 Mar 19;66(7):987-994. doi: 10.1093/cid/ciy149.

PMID:
29562266
21.

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.

Gerding DN, Kelly CP, Rahav G, Lee C, Dubberke ER, Kumar PN, Yacyshyn B, Kao D, Eves K, Ellison MC, Hanson ME, Guris D, Dorr MB.

Clin Infect Dis. 2018 Aug 16;67(5):649-656. doi: 10.1093/cid/ciy171.

22.

Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.

Avery RK, Silveira FP, Benedict K, Cleveland AA, Kauffman CA, Schuster MG, Dubberke ER, Husain S, Paterson DL, Chiller T, Pappas P.

Transpl Infect Dis. 2018 Jun;20(3):e12877. doi: 10.1111/tid.12877. Epub 2018 Mar 30.

23.

Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH.

Clin Infect Dis. 2018 Mar 19;66(7):e1-e48. doi: 10.1093/cid/cix1085.

24.

Epidemiology and outcomes of Clostridium difficile infection in allogeneic hematopoietic cell and lung transplant recipients.

Dubberke ER, Reske KA, Olsen MA, Bommarito K, Cleveland AA, Silveira FP, Schuster MG, Kauffman CA, Avery RK, Pappas PG, Chiller TM.

Transpl Infect Dis. 2018 Apr;20(2):e12855. doi: 10.1111/tid.12855. Epub 2018 Mar 6.

25.

Clostridium difficile control measures: current and future methods for prevention.

Mejia-Chew C, Dubberke ER.

Expert Rev Anti Infect Ther. 2018 Feb;16(2):121-131. doi: 10.1080/14787210.2018.1429911. Review.

PMID:
29353504
26.

Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection.

Prabhu VS, Dubberke ER, Dorr MB, Elbasha E, Cossrow N, Jiang Y, Marcella S.

Clin Infect Dis. 2018 Jan 18;66(3):355-362. doi: 10.1093/cid/cix809.

PMID:
29106516
27.

An Evaluation of the Prevalence of Vancomycin-Resistant Enterococci (VRE) and Methicillin-Resistant Staphylococcus aureus (MRSA) in Hospital Food.

Kwon JH, Reske KA, Hink T, Seiler SM, Wallace MA, Bommarito KM, Burnham CD, Dubberke ER.

Infect Control Hosp Epidemiol. 2017 Nov;38(11):1373-1375. doi: 10.1017/ice.2017.207. Epub 2017 Sep 27. No abstract available.

28.

Prediction of Recurrent Clostridium Difficile Infection Using Comprehensive Electronic Medical Records in an Integrated Healthcare Delivery System.

Escobar GJ, Baker JM, Kipnis P, Greene JD, Mast TC, Gupta SB, Cossrow N, Mehta V, Liu V, Dubberke ER.

Infect Control Hosp Epidemiol. 2017 Oct;38(10):1196-1203. doi: 10.1017/ice.2017.176. Epub 2017 Aug 24.

29.

Pathogenicity Locus, Core Genome, and Accessory Gene Contributions to Clostridium difficile Virulence.

Lewis BB, Carter RA, Ling L, Leiner I, Taur Y, Kamboj M, Dubberke ER, Xavier J, Pamer EG.

MBio. 2017 Aug 8;8(4). pii: e00885-17. doi: 10.1128/mBio.00885-17.

30.

Reducing Fluoroquinolone Use Is a Key Step in Controlling the Burden of Clostridium difficile Infection.

Walker T, Ciorba M, Dubberke ER.

Gastroenterology. 2017 Aug;153(2):606-607. doi: 10.1053/j.gastro.2017.06.048. Epub 2017 Jun 28. No abstract available.

PMID:
28668696
31.

Assessment of Healthcare Worker Protocol Deviations and Self-Contamination During Personal Protective Equipment Donning and Doffing.

Kwon JH, Burnham CD, Reske KA, Liang SY, Hink T, Wallace MA, Shupe A, Seiler S, Cass C, Fraser VJ, Dubberke ER.

Infect Control Hosp Epidemiol. 2017 Sep;38(9):1077-1083. doi: 10.1017/ice.2017.121. Epub 2017 Jun 13.

32.

Infections in Hematopoietic Cell Transplant Recipients: Results From the Organ Transplant Infection Project, a Multicenter, Prospective, Cohort Study.

Schuster MG, Cleveland AA, Dubberke ER, Kauffman CA, Avery RK, Husain S, Paterson DL, Silveira FP, Chiller TM, Benedict K, Murphy K, Pappas PG.

Open Forum Infect Dis. 2017 Mar 22;4(2):ofx050. doi: 10.1093/ofid/ofx050. eCollection 2017 Spring.

33.

Risk for Clostridium difficile Infection After Allogeneic Hematopoietic Cell Transplant Remains Elevated in the Postengraftment Period.

Dubberke ER, Reske KA, Olsen MA, Bommarito KM, Seiler S, Silveira FP, Chiller TM, DiPersio J, Fraser VJ.

Transplant Direct. 2017 Mar 17;3(4):e145. doi: 10.1097/TXD.0000000000000662. eCollection 2017 Apr.

34.

Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation.

Slade M, Goldsmith S, Romee R, DiPersio JF, Dubberke ER, Westervelt P, Uy GL, Lawrence SJ.

Transpl Infect Dis. 2017 Feb;19(1). doi: 10.1111/tid.12629. Epub 2016 Dec 28.

35.

Evaluation of Correlation between Pretest Probability for Clostridium difficile Infection and Clostridium difficile Enzyme Immunoassay Results.

Kwon JH, Reske KA, Hink T, Burnham CA, Dubberke ER.

J Clin Microbiol. 2017 Feb;55(2):596-605. doi: 10.1128/JCM.02126-16. Epub 2016 Dec 7.

36.

Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide.

Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Lawrence SJ, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Dubberke ER, Trinkaus K, Romee R.

Haematologica. 2016 Nov;101(11):e465-e468. Epub 2016 Jul 21. No abstract available.

37.

Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection.

Dubberke ER, Mullane KM, Gerding DN, Lee CH, Louie TJ, Guthertz H, Jones C.

Open Forum Infect Dis. 2016 Jun 20;3(3):ofw133. eCollection 2016 Sep.

38.

An Evaluation of Food as a Potential Source for Clostridium difficile Acquisition in Hospitalized Patients.

Kwon JH, Lanzas C, Reske KA, Hink T, Seiler SM, Bommarito KM, Burnham CD, Dubberke ER.

Infect Control Hosp Epidemiol. 2016 Dec;37(12):1401-1407. Epub 2016 Oct 3. Erratum in: Infect Control Hosp Epidemiol. 2017 Feb;38(2):258.

39.

Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, Cooper B, Dubberke ER, Engemann AM, Freifeld AG, Greene JN, Ito JI, Kaul DR, Lustberg ME, Montoya JG, Rolston K, Satyanarayana G, Segal B, Seo SK, Shoham S, Taplitz R, Topal J, Wilson JW, Hoffmann KG, Smith C.

J Natl Compr Canc Netw. 2016 Jul;14(7):882-913.

PMID:
27407129
40.

Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.

Gupta SB, Mehta V, Dubberke ER, Zhao X, Dorr MB, Guris D, Molrine D, Leney M, Miller M, Dupin M, Mast TC.

Clin Infect Dis. 2016 Sep 15;63(6):730-734. doi: 10.1093/cid/ciw364. Epub 2016 Jun 30.

PMID:
27365387
41.

Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach.

Desai K, Gupta SB, Dubberke ER, Prabhu VS, Browne C, Mast TC.

BMC Infect Dis. 2016 Jun 18;16:303. doi: 10.1186/s12879-016-1610-3.

42.

The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases.

Olsen MA, Young-Xu Y, Stwalley D, Kelly CP, Gerding DN, Saeed MJ, Mahé C, Dubberke ER.

BMC Infect Dis. 2016 Apr 22;16:177. doi: 10.1186/s12879-016-1501-7.

43.

Quantifying Transmission of Clostridium difficile within and outside Healthcare Settings.

Durham DP, Olsen MA, Dubberke ER, Galvani AP, Townsend JP.

Emerg Infect Dis. 2016 Apr;22(4):608-16. doi: 10.3201/eid2204.150455.

44.

Identification of Medicare Recipients at Highest Risk for Clostridium difficile Infection in the US by Population Attributable Risk Analysis.

Dubberke ER, Olsen MA, Stwalley D, Kelly CP, Gerding DN, Young-Xu Y, Mahé C.

PLoS One. 2016 Feb 9;11(2):e0146822. doi: 10.1371/journal.pone.0146822. eCollection 2016.

45.

Clostridium difficile-Diagnostic and Clinical Challenges.

Burnham CA, Dubberke ER, Kociolek LK, Polage CR, Riley TV.

Clin Chem. 2016 Feb;62(2):310-4. doi: 10.1373/clinchem.2015.243717. Epub 2015 Dec 11. No abstract available.

46.

Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors.

Young JH, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C, Knust K, Horowitz MM, Confer DL, Dubberke ER, Pergam SA, Marty FM, Strasfeld LM, Brown JWM, Langston AA, Schuster MG, Kaul DR, Martin SI, Anasetti C; Blood and Marrow Transplant Clinical Trials Network Trial 0201.

Biol Blood Marrow Transplant. 2016 Feb;22(2):359-370. doi: 10.1016/j.bbmt.2015.09.013. Epub 2015 Sep 25.

47.

Diagnosis of Clostridium difficile Infection: Treat the Patient, Not the Test.

Dubberke ER, Burnham CA.

JAMA Intern Med. 2015 Nov;175(11):1801-2. doi: 10.1001/jamainternmed.2015.4607. No abstract available.

PMID:
26348248
48.

Randomized Controlled Trial to Determine the Impact of Probiotic Administration on Colonization With Multidrug-Resistant Organisms in Critically Ill Patients.

Kwon JH, Bommarito KM, Reske KA, Seiler SM, Hink T, Babcock HM, Kollef MH, Fraser VJ, Burnham CA, Dubberke ER; Centers for Disease Control and Prevention (CDC) Prevention Epicenters.

Infect Control Hosp Epidemiol. 2015 Dec;36(12):1451-4. doi: 10.1017/ice.2015.195. Epub 2015 Aug 27.

49.

Ceftolozane-tazobactam activity against phylogenetically diverse Clostridium difficile strains.

Gonzalez MD, Wallace MA, Hink T, Dubberke ER, Burnham CA.

Antimicrob Agents Chemother. 2015 Nov;59(11):7084-5. doi: 10.1128/AAC.01670-15. Epub 2015 Aug 17.

50.

The Importance of Colonization with Clostridium difficile on Infection and Transmission.

Morgan DJ, Leekha S, Croft L, Burnham CA, Johnson JK, Pineles L, Harris AD, Dubberke ER.

Curr Infect Dis Rep. 2015 Sep;17(9):499. doi: 10.1007/s11908-015-0499-0.

PMID:
26239132

Supplemental Content

Loading ...
Support Center